Dergiler / The Journal of Pediatric Research / 2018 / Cilt: 5 - Sayı: 1

Demographic, Phenotypic and Genotypic Features of Alkaptonuria Patients: A Single Centre Experience

Sayfa
7–11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Here wereport on the clinical and genetic features of our patients at various ages.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Alkaptonuria (AKU) is an autosomal recessively inherited disease caused by a deficiency of homogentisate 1,2-dioxygenase.
📊
Temel Bulgular & Veri:In this study, we evaluated the demographic and clinical characteristics and also the mutations of our AKU patients.Materials and Methods: This retrospective single centre study included 36 patients who were diagnosed as AKU between the years of 2002 and 2017 ÇukurovaUniversity Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition.Results: Thirty six AKU patients were included (17 female, 19 male) in our study.
💡
Sonuç & Katkı:Here wereport on the clinical and genetic features of our patients at various ages.
🔬Tür:Araştırma Makalesi
📍Kapsam:2002 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Aim: Alkaptonuria (AKU) is an autosomal recessively inherited disease caused by a deficiency of homogentisate 1,2-dioxygenase. This enzyme convertshomogentisic acid (HGA) into maleylacetoacetic acid in the tyrosine degradation pathway. The presence of HGA in urine, ochronosis (bluish-blackpigmentation in connective tissues) and arthritis of the spine and the other large joints are the three major features of AKU. Nitisinone and a tyrosinerestricteddiet are the treatment options. In this study, we evaluated the demographic and clinical characteristics and also the mutations of our AKU patients.Materials and Methods: This retrospective single centre study included 36 patients who were diagnosed as AKU between the years of 2002 and 2017 ÇukurovaUniversity Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition.Results: Thirty six AKU patients were included (17 female, 19 male) in our study. The mean age of the patients was 9.3±13.4 years (3 months-54 years). The major complaintswere darkening of the urine (100%), ochronosis (11.1%), arthralgia (16.7%) and arthritis (8.1%). Darkening of the urine was firstly recognized at the age of 8.89±16.9 months(1-84 months). Eighteen (86%) patients had homozygous and 3 (14%) patients had compound heterozygous mutations in the HGD gene.Conclusion: AKU was the first inherited metabolic disease defined. The three main features are; darkening of the urine at birth which is followed by ochronosis (blue-darkpigmentation) clinically visible in the ear and alae of the nose and finally a severe ochronotic arthropathy of the spine and large joints at around the age of 50 years. Here wereport on the clinical and genetic features of our patients at various ages.

🔖

Bu Makaleye Atıf Yap

KILAVUZ, S., BULUT, F. D., KOR, D., YILMAZ, B. Ş., BAŞARAN, S., SARPEL, T., MUNGAN, N. Ö. (2018). Demographic, Phenotypic and Genotypic Features of Alkaptonuria Patients: A Single Centre Experience. The Journal of Pediatric Research, Cilt: 5 - Sayı: 1, 7–11. https://ajindex.com/articles/362920

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J Biol Med 2002;75:221-31.
  2. Mannoni A, Selvi E, Lorenzini S, et al. Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum 2004;33:239-48.
  3. Arnoux JB, Le Quan Sang KH, et al. Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria. J Inherit Metab Dis 2015;38:791-6.
  4. Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria--a review of surgical and autopsy pathology. Histopathology 2008;53:503-12.
  5. Hannoush H, Introne WJ, Chen MY, et al. Aortic stenosis and vascular calcifications in alkaptonuria. Mol Genet Metab 2012;105:198-202.
  6. Anikster Y, Nyhan WL, Gahl WA. NTBC and alkaptonuria. Am J Hum Genet 1998;63:920-1.
  7. Suwannarat P, O’Brien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005;54:719-28.
  8. Tinti L, Spreafico A, Braconi D, et al. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol 2010;225:84-91.
  9. Capkin E, Karkucak M, Yayli S, Serdaroğlu M, Tosun M. Ochronosis in differential diagnosis of patients with chronic backache: a review of the literature. Rheumatol Int 2007;28:61-4. Epub 2007 Jun 13 Thomas M, Jebaraj JI, Thomas M, George R. Acral pigmentation in alkaptonuria resembling degenerative collagenous plaques of the hands: a report of five cases. J Am Acad Dermatol 2011;65:e45-6. Odom RB JW, Berger TG. Diseases of the Skin. 9th ed ed. Error in metabolism. 2000, Philadelphia: WB Saunders Company. Uyguner O, Goicoechea de Jorge E, Cefle A, et al. Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58fs mutation originated from central Asia and was spread throughout Europe and Anatolia by human migrations. J Inherit Metab Dis 2003;26:17-23. http://hgddatabase.cvtisr.sk/.
  10. Yang YJ, Guo JH, Chen WJ, et al. First report of HGD mutations in a Chinese with alkaptonuria. Gene 2013;518:467-9.
  11. Zatkova A, Sedlackova T, Radvansky J, et al. Identification of 11 Novel Homogentisate 1,2 Dioxygenase Variants in Alkaptonuria Patients and Establishment of a Novel LOVDBased HGD Mutation Database. JIMD Rep 2012;4:55-65. Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis 2011;34:1127-36. Zatkova A, de Bernabe DB, Polakova H, et al. High frequency of alkaptonuria in Slovakia: evidence for the appearance of multiple muta